Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199039 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL2567234 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL14428300 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL1178180 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL25765827 | 0.90 | HSD17B10 (0.47) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL2902862 | 0.90 | HSD17B10 (0.47) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL17679813 | 0.90 | HSD17B10 (0.47) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL30742973 | 0.90 | HSD17B10 (0.47) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL24439022 | 0.89 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HSD17B10HPGD | |
| SCHEMBL31239983 | 0.89 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20240228510-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-07-11 | — | — | US | disclosed |
| WO-2024075696-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | 公立大学法人横浜市立大学 | 2024-04-11 | — | — | WO | disclosed |
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4322945-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648452-A | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| CN-116194456-A | Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof | 上海科州药物研发有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| US-20040248779-A1 | Process for the preparation of macrocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228510-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1535/4885CHRM2 4880/4885CHRM1 4874/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | NR1H2 1539/4885CHRM2 4880/4885CHRM1 4874/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | NR1H2 2161/4885CHRM2 4366/4885CHRM1 4285/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | NR1H2 2227/4885CHRM2 4558/4885CHRM1 4599/4885 |
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | KRAS, NRAS, HRAS | NR1H2 1327/4885CHRM2 4737/4885CHRM1 4306/4885 |
| US-20070066626-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | NR1H2 2912/4885CHRM2 469/4885CHRM1 617/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | NR1H2 781/4885CHRM2 79/4885CHRM1 51/4885 |
| US-20040248779-A1 | Process for the preparation of macrocyclic compounds | CCND2, CYP1B1, PRMT1 | NR1H2 1545/4885CHRM2 1708/4885CHRM1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.